Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) EBIT Margin (2020 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed EBIT Margin for 11 consecutive years, with 59.02% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin fell 11129.0% year-over-year to 59.02%, compared with a TTM value of 87.71% through Dec 2025, up 3031.0%, and an annual FY2025 reading of 46.46%, up 29780.0% over the prior year.
  • EBIT Margin was 59.02% for Q4 2025 at Neuroone Medical Technologies, down from 50.02% in the prior quarter.
  • Across five years, EBIT Margin topped out at 52.26% in Q4 2024 and bottomed at 13134.27% in Q1 2021.
  • Average EBIT Margin over 5 years is 2954.78%, with a median of 653.59% recorded in 2023.
  • The sharpest move saw EBIT Margin crashed -532557bps in 2021, then skyrocketed 805902bps in 2023.
  • Year by year, EBIT Margin stood at 8324.42% in 2021, then skyrocketed by 81bps to 1557.31% in 2022, then skyrocketed by 78bps to 346.8% in 2023, then surged by 115bps to 52.26% in 2024, then crashed by -213bps to 59.02% in 2025.
  • Business Quant data shows EBIT Margin for NMTC at 59.02% in Q4 2025, 50.02% in Q3 2025, and 111.23% in Q2 2025.